In a report released today, Geulah Livshits from Chardan Capital reiterated a Hold rating on Vascular Biogenics (VBLT), with a price target of $3. The company’s shares opened today at $1.20.
According to TipRanks.com, Livshits is a 1-star analyst with an average return of -2.4% and a 25.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.
Currently, the analyst consensus on Vascular Biogenics is a Moderate Buy with an average price target of $3.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.10 and a one-year low of $0.60. Currently, Vascular Biogenics has an average volume of 108.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.
